3 different formulations and doses of tafamidis will be compared. Subjects will be fasted for each test and every subject will test all 3 different formulations. After swallowing tafamidis, tafamidis blood concentrations will be measured periodically for 6 days. After 14 days, subjects will take a different formulation of tafamidis and tafamidis blood concentrations will be measured periodically for 6 days. After another 14 days, the last formulation will be tested in the same way.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
Pfizer Clinical Research Unit
Brussels, Belgium
Area under the concentration-time Curve (AUC)
Time frame: 120 hours
Maximum Observed Plasma Concentration (Cmax)
Time frame: 120 hours
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Time frame: 120 hours
Mean residence time (MRT)
Time frame: 120 hours
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 120 hours
Plasma Decay Half-Life (t1/2)
Time frame: 120 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.